Hope HC posters here aren't letting the ZIP troll scare them off.
Has anyone notice any incorrect factual statements in the Q&A?
The Opthea GPT I created pulls from 55 documents and PDFs from the last two years, which I’ve mined and summarized before loading as knowledge into the GPT. There’s a lot of unstructured info in there. Does anyone have any questions they’d like to see added?
One thing I’m particularly interested in is the interplay between EyeBio’s Restoret (EYE103), which focuses on retinal vascular leakage and is now controlled by "BP": Merck. As I understand it, it’s currently in Phase 2, about a year behind. Could restoret have a material impact on OPT? , but it’s been tough to quantify whether that drug, if successful, would be a direct competitor or complement Sozinibercept in treatment plans for wet AMD?.
Anyone want to take a shot at a Q&A on the potential impact of Restoret?
Hope HC posters here aren't letting the ZIP troll scare them...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
76.5¢ |
Change
-0.025(3.16%) |
Mkt cap ! $929.4M | |||
| Open | High | Low | Value | Volume |
| 79.0¢ | 79.0¢ | 74.5¢ | $664.0K | 867.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 5682 | 76.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 77.0¢ | 25847 | 10 |
View Market Depth
| Last trade - 12.01pm 27/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |